Browse drugs

…d to analyse the physicochemical stability and compatibility of ceftriaxone sodium (CEF) (2mg/mL) with pantoprazole sodium (PAN) (0.08mg/mL) and o…

… as well as repurposed and novel agents such as clofazimine and delamanid. In addition, a large number of novel antimicrobial and host di…

…erans Affairs healthcare system with type 2 diabetes initiating GLP-1RA (n=132 551) or sulfonylureas (n=201 136) between 1 January 2017…

…dexmedetomidine, flucloxacillin, furosemide, heparin, ketamine, metamizole) for which specific data are lacking.Method Forty-six binary 1:…

…-CD20 therapy (768 on rituximab and 509 on ocrelizumab) and 677 natalizumab. Natalizumab significantly reduced ARR compared with anti-CD20 …

…nistered via the same line as PN (esomeprazole, chlorphenamine, milrinone, midazolam, rocuronium, furosemide and magnesium sulphate). No …

…een put forward for consideration in treating high-risk TA-TMA; eculizumab, narsopilmab, rituximab, defibrotide, ravulizumab, nomacopan, p…

…ssion quartiles in a subgroup of patients with CRC treated with pembrolizumab (n=500). The CXCR4high cohort showed significantly improved sur…

…l (axi-cel), 31 (42%) tisagenlecleucel (tisa-cel), and 11 (16%) brexucabtagene autoleucel (brexi-cel). Mean V2Vt was 48±19 days (median 42) for axi-cel, …

…ain—ranibizumab, aflibercept (2 mg and 8 mg), brolucizumab, and faricimab—each differing in dosing interval, mechanism, and cost. Compara…

…e had no effect on physicochemical characteristics. The optimal gentamicin ophthalmic formulation (1.36%) should be prepared by dissolving…

…ti-angiogenic therapy, mainly aflibercept and bevacizumab, with faricimab as a second-line option. Personalised treatments and optimised …